Related Experiment Video
Updated: Aug 6, 2026
Multiplexed Live-Cell Imaging for Drug Responses in Patient-Derived Organoid Models of Cancer
Published on: January 5, 2024
Cell death induced by MPPa-PDT in prostate carcinoma in vitro and in vivo
Yuanyuan Tian1, Wingnang Leung, Kinman Yue
1Department of Biochemistry, School of Medicine, Shandong University, Jinan, China.
Abstract:
Lack of effective photosensitizers has become a major limit for extensive application of photodynamic therapy. In this study, the photocytotoxicity and mode of death induced by a newly developed photosensitizer MPPa, a derivative of chlorophyll a, were investigated in PC-3M cell line, a highly metastatic variant of poorly differentiated androgen-independent proctanec adenocarcinoma PC-3. MTT reduction assay was used to measure cytotoxicity in both PC-3M and HUVEC, after which a flow cytometer was used to measure apoptotic rate and cell cycle, and then Caspase-3, -8, -9 were investigated. Finally, an animal model was set up to embody the curative effect and for histopathological examinations. The photocytotoxicity of MPPa showed both light- and drug-dose dependent characteristics and no significant dark cytotoxicity was observed in PC-3M cells. In HUVEC, MPPa exhibited an obviously low cytotoxicity. By other in vitro studies, we found MPPa-PDT induced apoptotic mainly via the mitochondrial/Caspase-9/Caspase-3 pathway and could restrain the cell cycle progression from the more sensitive G0/G1-phases. In vivo, the tumour growth was significantly inhibited after PDT, and many apoptotic cells could be seen by histopathological examinations. These results indicate the death way of cells induced by MPPa is mainly via mild apoptotic and the cure effect is obvious, suggesting that MPPa is a potential photosensitizer of photodynamic therapy for prostate cancer.
Insights
A new chlorophyll a derivative, MPPa, shows effectiveness as a photosensitizer for photodynamic therapy (PDT) in prostate cancer. MPPa-PDT effectively inhibits tumor growth by inducing apoptosis with minimal dark toxicity.
Area of Science:
- Biochemistry
- Oncology
- Photochemistry
Background:
- Photodynamic therapy (PDT) efficacy is limited by the availability of effective photosensitizers.
- Prostate cancer, particularly advanced forms, requires novel therapeutic strategies.
Purpose of the Study:
- To investigate the photocytotoxicity and cell death mechanisms of a novel chlorophyll a derivative, MPPa, in prostate cancer cells.
- To evaluate the therapeutic potential of MPPa-mediated PDT in preclinical models.
Main Methods:
- In vitro studies using PC-3M prostate cancer cells and HUVEC cells.
- MTT assays for cytotoxicity, flow cytometry for apoptosis and cell cycle analysis.
- Caspase activity assays and in vivo animal models with histopathological examination.
Main Results:
- MPPa demonstrated dose-dependent photocytotoxicity in PC-3M cells with negligible dark toxicity.
- MPPa-PDT induced apoptosis primarily through the mitochondrial pathway (Caspase-9/Caspase-3) and arrested cells in G0/G1 phase.
- Significant tumor growth inhibition and observable apoptosis were noted in vivo.
Conclusions:
- MPPa is a promising photosensitizer for PDT in prostate cancer treatment.
- MPPa-PDT effectively induces apoptosis and inhibits tumor growth with a favorable safety profile.
